CatalYm today announced that the first patient has been dosed in the Phase 2/3 VINCIT trial (Visugromab IN Cachexia ...

An Oregon veteran's 16-year fight with the VA over benefits for inclusion body myositis, or IBM, is part of a growing ...

Inclusion body myositis (IBM) is a slowly progressive muscle-wasting disease that typically starts with weakness in the hands and upper legs and often leads to difficulty swallowing. There is no cure, ...

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive vectorized gene therapies with minimally-invasive delivery technology, will be presenting the results ...

An international research team with the participation of researchers from the University Medical Center Göttingen (UMG), ...

This Morning presenter Ben Shephard shared his encouragement to a colleague who spoke openly about his MND diagnosis on the ...

The owner of the now-shuttered West Coast Game Park Safari pleaded guilty Monday morning to more than 40 charges of ...

Oral medicine subsidies for patients aged 25 or above began early this year but adults still lack public funding for ...

The U.S. Food and Drug Administration (FDA) has approved the granule formulation of Neurocrine Biosciences' Ingrezza drug to treat movement disorders associated with Huntington's disease (HD), the ...

Jesy Nelson shared an adorable video of her twin babies babbling, jokingly captioning that she will get “no rest”. The former ...

Former England captain Lewis Moody, who was diagnosed with motor neurone disease last year, announces a cycling challenge to ...

Scientists sum up the evidence—or lack thereof—for the most popular peptides hyped for athletic performance and recovery.